1. Importance of Iron in Human Health
Iron is an essential trace mineral for normal biological function in almost all organisms. In order to maintain baseline homeostasis and resupply the minor unregulated loss of iron, 25 mg/day of iron is required for a human adult. About 65% of the total iron in humans is stored in RBCs in the form of hemoglobin, 20% is allocated in macrophages and hepatocytes, 10% is distributed in muscle fibers as myoglobin, and 5% is in bone marrow
[1].
Under physiological conditions, there are two main sources of iron absorption in the body, namely endogenous iron absorption and exogenous iron absorption (
Figure 1). Endogenous absorption is mainly from the recycling of iron from senescent erythrocytes. In the process of clearance of aging or damaged erythrocytes, macrophages phagocytose the erythrocytes and decompose heme, a component of hemoglobin with iron bonded, using heme oxygenase 1 (HO-1) to release iron, which can be recycled back into circulation by the iron exporter ferroportin (FPN), a transmembrane protein on the cell surface (
Figure 1). Exogenous iron absorption mainly refers to dietary iron. Generally, about 1~2 mg of iron, in the form of either heme iron (Fe
2+) or non-heme iron (Fe
3+), is absorbed daily by duodenal enterocytes through different mechanisms (
Figure 1). Fe
2+ is directly absorbed in the apical surface of enterocytes via iron transport protein, divalent metal transporter 1 (DMT1), whereas Fe
3+ is not bioavailable and needs to be converted to Fe
2+ by duodenal cytochrome B (DcytB), a converting enzyme, before being absorbed by the apical membrane of duodenal enterocytes via DMT1
[2]. Absorbed iron in duodenal enterocytes can be transported through FPN into the circulation to play its physiological role
[3].
Figure 1. Iron absorption, recycling, and storage under physiological conditions. Exogenous iron absorption and endogenous iron recycling are two sources of iron in the human body. During the process of iron absorption and recycling, DcytB and DMT1 are responsible for the uptake of Fe
2+ from the lumen, and macrophages are in charge of the cyclic utilization of iron from senescent erythrocytes. In addition, excess iron is usually stored in the hepatocyte in the form of ferritin, and FPN can export Fe
2+ into the blood. FPN, ferroportin; HO-1, heme oxygenase 1; CP, ceruloplasmin; DcytB, duodenal cytochrome B; DMT1, divalent metal transporter 1 (modified according to Abbasi et al., 2021
[4]).
To maintain iron homeostasis, hepcidin, a peptide hormone secreted by the liver, plays an important role by regulating the expression of FPN on the cell surface. Hepcidin can reduce FPN expression by binding FPN and inducing its internalization and degradation in lysosomes. In physical conditions, the absorbed iron can be stored and iron can be transported into the bloodstream via FPN. When iron levels exceed the body’s requirements, the increased secretion of hepcidin inhibits FPN expression, resulting in reduced iron transportation from cells into the blood circulation
[5].
Transferrin (Tf), an iron transport protein, is responsible for the transportation and distribution of almost all iron within circulating blood (
Figure 1). Specifically, most of the iron in the bloodstream exists in the form of Fe
3+. About 25~30 mg/day of iron can be delivered by Tf from plasma to developing erythroid cells in the bone marrow for heme biosynthesis. Lower amounts of iron, up to 5 mg/day, are supplied to other tissues via Tf in order to meet various physiological needs. The pathway for iron transportation from Tf into cells is not fully defined, but the current evidence suggests that it involves endocytosis of the transferrin receptor (TfR) complex; the binding force between Tf and Fe
3+ is then reduced, so as to allow for the release of iron from transferrin
[6]. As a result, the free iron can then move into the cytoplasm and be used by the cell.
Under normal conditions, iron above immediate cell needs is safely stored within ferritin. Ferritin, as a hollow globular protein, is usually composed of 24 H and L subunits, so it can store up to 4500 ferrous ions. Furthermore, because hepatocytes are the major site for ferritin synthesis, the liver is the primary iron storage organ. In addition, some recycled iron is reincorporated into the bone marrow. When the iron demand increases, the stored iron in both the liver and bone marrow is mobilized to increase the iron content in circulation.
Serving as a prosthetic group for a variety of proteins, iron plays an important role in various vital physiological processes of cells. For example, iron is required for cell viability and proliferation. Iron functions as a catalyst for enzymes and plays a key role in DNA synthesis and repair, and cellular energy metabolism. Moreover, iron is also thought to play a role in the immune system. However, iron overload can attenuate the phagocytosis of macrophages, and affect the function of T lymphocytes, so as to disrupt the immune response
[7][8].
By acquiring iron from hosts, invading microbes can also utilize iron to promote their own growth, disturb the homeostatic balance of the body, and bring potential adverse consequences
[9][10][11]. Therefore, it is a physiological challenge to maintain the balance of the body’s requirement for iron, particularly in states of infection and inflammation.
2. Iron Regulation
In order to maintain an appropriate iron balance, organisms have evolved complex systemic homeostatic and cellular iron transport mechanisms. For example, hepcidin, produced primarily by hepatocytes, is the key regulator of systemic iron homeostasis. When the iron circulating concentration is increased in plasma, the body responds by elevating hepcidin release, which can downregulate FPN mRNA and protein levels, reducing the efficiency of delivering iron from storage sites to plasma, and thus lowering the plasma iron level
[5][12]. Similarly, when the iron concentration is decreased, the body responds by reducing hepcidin release, which can upregulate the expression levels of FPN, partly resulting in a recovery of iron reabsorption and an increase in iron concentration
[8].
In addition to the hepcidin/FPN pathway, the iron regulatory protein/iron-responsive elements (IRP/IRE) system also plays a key role in maintaining iron homeostasis. IREs are mainly located in the untranslated regions of mRNAs encoding proteins related to the absorption, storage, utilization, and export of iron. Interestingly, the 5′-end IREs mainly regulate gene expression related to iron storage and transport, such as ferritin and FPN. However, the 3′-end IREs are closely related to the expression of iron absorption genes, such as TfR1 and DMT1. Moreover, IRP1 and IRP2, via binding to IREs of the 5′ and 3′ regions, can control the mRNA translation or stability. Generally, the translation of the mRNAs, including ferritin and FPN, will be inhibited under the condition of IRPs combined with 5′ IREs, whereas the stability of mRNAs, including TfR1 and DMT1, will be reinforced when IRP binds to 3′ IREs. For example, under iron overload conditions, IRP1 is converted to c-aconitase by SCF (SKP1-CUL1-F-box) E3 ligase complex and IRP2 is degraded by proteasomes, resulting in decreased IRP binding to IREs. This dissociation of IRP–IRE interaction will increase the translation of FPN and ferritin mRNA and disturb TfR1 and DMT1 mRNA, resulting in an increase in iron storage and export and a decline in iron absorption
[13][14][15][16].
Recent studies in mouse models have begun characterizing the roles of zinc transporter SLC39A8 (ZIP8) and other soluble proteins in regulating body iron homeostasis. ZIP8 is a zinc transporter and is encoded by the SLC39A8 gene, and has also been proven to have the ability to import iron into the cytosolic space
[17]. In in vitro and animal studies, ZIP8 expression can be greatly increased after inflammatory stimulation with LPS, suggesting that increased ZIP8 via iron transporting has a function in host defense
[18][19] (
Figure 2). Lipocalin-2 is a soluble protein and is secreted by epithelial cells and neutrophils, and can also promote cellular and tissue iron uptake through the siderophore–lipocalin-2 complex. It is reported that circulating concentrations of lipocalin-2 are positively associated with adiposity, hypertriglyceridemia, hyperglycemia, insulin resistance, and circulating levels of C-reactive protein. Moreover, lipocalin-2 can bind to iron with a much higher affinity than the endogenous carrier protein transferrin, thus potentially aiding pathogen survival and growth during infection
[11][20][21].
Figure 2. Proposed iron regulation in lung. The level of iron in alveolar epithelial cells is mainly regulated by TfR1, DMT1, ZIP8, LfR, and FPN receptors. Alveolar macrophages, through phagocytosis of bacteria, play an important role in lung defense response. Fpn, ferroportin; ZIP8, zinc transporter SLC39A8; Lfn, lactoferrin; LfR, lactoferrin receptor; DMT1, divalent metal transporter 1; TfR1, transferrin receptor 1; NRAMP1, natural resistance–associated macrophage protein 1NGAL, neutrophil gelatinase–associated lipocalin (modified according to Zhang et al., 2019
[22]).
3. Iron in Pathology and Diseases
Iron deficiency results in the impairment of multiple cellular functions and, in particular, erythropoiesis and red blood cell heme contents are reduced
[4][23]. Research has demonstrated that iron deficiency is associated with up to 60% of patients with cardiovascular disease, including coronary artery disease, heart failure, and pulmonary hypertension. In elderly patients with reduced ejection fraction, both anemia and iron deficiency may confer independent risk due to a poor prognosis
[24]. Iron deficiency is usually caused by an underlying inflammatory disease, such as inflammatory bowel disease (IBD) or chronic kidney disease (CKD)
[25]. In IBD, iron deficiency is markedly associated with decreased intestinal iron absorption, malnutrition, chronic inflammation, and blood loss. In patients diagnosed with CKD, anemia is induced by disturbed renal erythropoietin (EPO) production, which is responsible for erythropoiesis. Iron supplementation or recombinant EPO have been used to improve anemia in these patients
[26]. In addition, iron deficiency is closely related to tumor progression. At the cellular level, the expression of iron metabolism–related proteins is altered in cancer. For example, TfR1 and DMT1, which increase iron uptake, are highly overexpressed in many tumor types, increasing intracellular iron levels
[27][28]. Also, it is reported that FPN, which is in charge of iron release, is downregulated in prostate and breast cancer
[29][30]. Therefore, iron deficiency, especially iron-deficiency anemia, has become one of the most important contributors to the global burden of disease, which mainly affects children, as well as people in low-income countries
[31].
On the other hand, iron overload also has adverse consequences for the host, including oxidative stress, vascular dysfunction, ferroptosis, and peroxidation of lipid membranes
[32][33][34]. Generally, under pathological conditions, iron overload mainly refers to non-transferrin-bound iron. Because humans lack a proper physiological pathway to clear out iron, it is important for iron to be maintained in homeostasis via a complex feedback mechanism between iron uptake, utilization, and storage. However, under pathological conditions, this balance will be disturbed. Initially, the excess iron can be safely combined with transferrin or stored in ferritin. However, transferrin will be saturated quickly by an accumulation of iron, raising the level of non-transferrin-bound-iron, which is rapidly taken up by various organs. As a result, the body will have a pathological situation of iron overload, resulting in organ damage. For example, a clinical study showed that due to high glucose toxicity in diabetic patients, the release of serum iron was inhibited, which resulted in iron overload. What is more, by facilitating lipid peroxidation and catalyzing excess hydroxyl free radicals, the increase of serum iron can promote the occurrence of acute kidney injury (AKI); therefore, iron overload is considered an independent risk factor for AKI in critically ill patients with diabetes
[35]. It is also reported that iron is necessary for the continuous and rapid proliferation of cancer cells, resulting in accelerated cancer cell growth and increased morbidity and mortality in cancer patients
[8]. Moreover, excess iron can promote the generation of free radicals and reactive oxygen species, which damage healthy cells and induce inflammation.
Furthermore, increased iron availability is also associated with the increased virulence of multiple microbial pathogens
[36][37]. Toni et al. described the link between iron overload and an increased susceptibility to various invasive fungal infections, and suggested that reducing the level of iron may be a better way to prevent infections in patients with hematological malignancies
[38]. Although different bacteria and viruses have different ways of acquiring and utilizing iron, they all use iron with the same goal of promoting their own growth, increasing virulence, and ultimately increasing pathogenicity. Therefore, the use of iron chelators to limit iron availability and control microbial survival may be a useful way to hinder the development of infections
[39].